If you are a Medicare beneficiary, you might reasonably ask why Medicaid abortion reimbursement rates belong in your reading. The answer is structural. Millions of Americans move between Medicaid and Medicare through dual eligibility, spend-down programs, and coverage transitions — and the two programs share provider networks in nearly every community in the country. When Medicaid pays providers inadequately for any category of service, it creates financial pressure that can reduce provider participation, close clinics, and shrink the pool of doctors and facilities available to everyone in that community, including Medicare patients. Understanding how Medicaid pays is part of understanding the healthcare landscape you actually live in.
As of 2026, 21 states use their own state-appropriated funds to pay for abortion services for Medicaid enrollees beyond what federal law permits. The Hyde Amendment, attached to federal spending bills continuously since 1976, prohibits the use of federal Medicaid dollars for abortion except in three narrow circumstances: when the pregnancy results from rape, when it results from incest, or when continuing the pregnancy would endanger the life of the pregnant person. States that want to cover abortion more broadly must do so entirely with state funds — no federal matching dollars are available for those additional services. That means the 21 states doing this work are bearing 100 cents of every dollar they spend on this coverage.
Among those 21 states, the variation in what Medicaid actually pays for the same procedure is striking. For medication abortion — the two-drug regimen using mifepristone and misoprostol — reimbursement rates range from $162 in Rhode Island to $869 in Washington state, with a national median of $597. That is a difference of more than $700 for an identical clinical service, determined entirely by which state a patient happens to live in. For dilation and curettage, a surgical procedure typically used earlier in pregnancy, rates span from $126 in Rhode Island to $1,000 in New York, with a median of $378. For dilation and evacuation, a more complex procedure generally used later in pregnancy, the range runs from $126 in Rhode Island to $1,920 in Illinois, with a national median of $636.
Rhode Island sits at the absolute floor across all three procedure categories — $126 for both D&C and D&E, and $162 for medication abortion. To put $126 in perspective: that is less than the cost of a standard specialist office visit copay under many Medicare Advantage plans, and far below what most providers spend in staff time, facility overhead, supplies, and liability coverage to perform a surgical procedure. When a state pays $126 for a surgical abortion, it is effectively telling providers that accepting Medicaid patients for this service will cost them money. That math discourages participation, which limits access even in states where the service is legally covered and nominally reimbursed.
The inflation problem compounds the access problem in ways that are easy to overlook. A KFF analysis found that among states that increased D&C reimbursement rates over the past two years, only five did so at or above the rate of healthcare inflation. For D&E procedures, only six states kept pace with inflation. Meanwhile, 57 percent of states covering abortion for Medicaid enrollees — 12 states — have not increased D&C reimbursement rates at all in two years, and 52 percent, or 11 states, have not increased D&E rates. In an environment where healthcare input costs have risen meaningfully since 2022, a frozen reimbursement rate is a real-dollar pay cut for providers. The practical consequence is that even in states with legal abortion access and nominal Medicaid coverage, the financial infrastructure supporting that coverage is quietly eroding.
The complexity gap in reimbursement deserves its own examination. D&E procedures, performed later in pregnancy, involve greater clinical complexity than D&C procedures performed earlier. Later-stage procedures require more provider time, more specialized training, more equipment, and carry higher clinical risk. Yet the national median reimbursement for D&E is $636 — only $258 more than the $378 median for D&C, a 68 percent premium for a procedure that is substantially more resource-intensive. Research on self-pay abortion charges — what providers bill patients paying out of pocket — shows rates considerably higher than these Medicaid figures, which suggests that Medicaid reimbursement is not calibrated to actual market costs. When the gap between what a procedure costs to deliver and what Medicaid pays becomes wide enough, providers stop accepting Medicaid for that service. That is not a hypothetical; it is a documented pattern across multiple Medicaid service categories.
For dual-eligible beneficiaries — people enrolled in both Medicare and Medicaid simultaneously — this matters in a direct and personal way. According to CMS.gov data, approximately 12.5 million Americans were enrolled in both programs as of recent reporting periods. These individuals rely on Medicaid to cover costs that Medicare does not, including certain services, long-term care, and in some states, reproductive health services. When Medicaid reimbursement rates are inadequate, the providers who accept dual-eligible patients may be fewer in number, harder to reach geographically, or operating under financial stress that affects the quality and continuity of care they can provide. A clinic that stops accepting Medicaid for one service category often reduces its overall Medicaid caseload, which affects every patient it would have served.
Data Snapshot: According to CMS.gov data, Medicaid covered approximately 86 million individuals as of early 2026, making it the largest single health coverage program in the United States by enrollment. Women of reproductive age represent a significant share of that population and are the demographic most directly affected by the reimbursement disparities documented in this analysis. CMS publishes Medicaid payment data through its Medicaid and CHIP Payment and Access Commission reporting infrastructure, though state-specific abortion reimbursement rates are not centrally tracked by CMS and must be gathered through direct state agency inquiry or research compilations. Separately, CMS data shows that more than 3,800 Medicare Advantage plans were available nationally in 2026 — none of which alter the underlying Medicaid reimbursement structure for services Medicaid covers independently, and none of which cover abortion as a Medicare benefit.
The post-Dobbs landscape has also reshuffled which states are doing the coverage work. Since the Supreme Court's 2022 Dobbs decision overturned Roe v. Wade, 13 states have enacted near-total abortion bans with limited exceptions. In those states, the question of Medicaid reimbursement rates is moot — the services are not legally available regardless of what Medicaid would pay. The 21 states using state funds to cover abortion are, in effect, the entire universe where this reimbursement policy question is live. That concentration makes the underfunding problem more consequential: a smaller number of states are bearing the full policy and financial burden of providing this coverage, and within that group, the variation in actual commitment — as measured by reimbursement rates — is enormous. Washington state's $869 medication abortion rate and Rhode Island's $162 rate represent two very different levels of policy seriousness, even though both states technically offer coverage.
For Medicare beneficiaries who are caregivers, advocates, or family members of someone on Medicaid — or who are dual-eligible themselves — there are concrete steps worth taking. Contact your State Medicaid agency directly to ask about covered services and current reimbursement rates in your state. If you are in a Medicaid managed care plan, your plan's member services line can clarify which providers in your network accept Medicaid for specific services. The Kaiser Family Foundation maintains updated state-by-state Medicaid policy data at kff.org, which allows you to compare your state's reimbursement approach against national benchmarks. If you believe you have been denied a covered service or cannot find a participating provider, your State Insurance Commissioner's office can provide guidance on coverage disputes and patient rights under Medicaid managed care.
For Medicare Advantage enrollees specifically, it is worth being clear about what Medicare does and does not cover. Medicare itself — both Original Medicare and Medicare Advantage — does not cover abortion as a standard benefit. This is a separate policy framework from Medicaid. However, beneficiaries who are dually enrolled in both programs, or who are considering Medicaid spend-down to qualify for long-term care coverage, should understand that Medicaid's reproductive health coverage rules and reimbursement rates will vary significantly by state of residence. Knowing your state's position — whether it is one of the 21 covering abortion with state funds, and what it actually pays providers — is part of understanding the full scope of your coverage.
The broader policy takeaway from this 2026 analysis is that legal access to a service and meaningful access to a service are not the same thing. A state can technically cover abortion for Medicaid enrollees while simultaneously setting reimbursement rates so low that few providers can afford to participate. The result is coverage on paper that does not translate to care in practice. For a population that already faces significant socioeconomic barriers to healthcare, inadequate reimbursement rates represent a structural obstacle layered on top of existing ones. Rural communities are particularly vulnerable to this dynamic, since they often have fewer providers to begin with and less redundancy in the system when one practice reduces its Medicaid caseload. Policymakers, patient advocates, and healthcare systems all have roles to play in closing the gap between what states promise to cover and what they actually pay providers to deliver — and Medicare beneficiaries who share those provider networks have a stake in that outcome.